



Sterilox Technologies Appoints Keith Goldan as Chief Financial Officer

Radnor, Pa., [11/24/04] – Sterilox Technologies, Inc. announced the appointment of Keith A. Goldan, CPA, as Chief Financial Officer.

Goldan brings to Sterilox more than 12 years of experience in business planning and financial management in the healthcare industry.

“Sterilox is committed to building value for its stakeholders, and Keith’s healthcare background combined with his experience in financial oversight of rapidly growing companies are both strong elements that support our goals,” said Chris Wightman, Sterilox’s chairman of the board.

“With Keith’s appointment, and the election of Gregory T. Bosch as president and CEO, Sterilox has a dynamic leadership team in place to carry us into the future,” continued Wightman.

“I am proud to be a part of the Sterilox team and I look forward to working closely with Greg Bosch to formulate an executive plan and strategies to meet the board’s mandates to bring about long-term value for the company’s employees, customers, shareholders and creditors,” Goldan said.

Prior to joining Sterilox, Goldan held a variety of strategic financial planning positions in the healthcare and life sciences industries. Most recently, he was vice president and CFO of Biosyn, Inc., where he successfully executed the sale of the privately held, venture-backed biotechnology company to Cellegy Pharmaceuticals, a publicly traded company. He also has worked with ViroPharma Incorporated; Century Capital Associates, a consulting firm specializing in capital strategy for healthcare clients; and with the Health Care & Life Sciences Practice of KPMG LLP.

Goldan received his bachelor’s degree in Business Management (Finance), *cum laude*, from the University of Maryland and holds a master’s in Business Administration from the University of Pennsylvania’s Wharton School of Business.

About Sterilox:

Sterilox Technologies, Inc., formed in 1997 and headquartered in Radnor, Pa., is a medical technology company engaged in the development and commercialization of novel solutions based on its patented platform technology. Sterilox has a portfolio of non-toxic, non-hazardous, fast-acting, broad-spectrum biocides. These disinfectants were developed for both rapid and cold sterilization of heat-sensitive surgical instruments such as endoscopes, as well as for general disinfectant use in hospitals, the dental market and the food and hospitality industry.

The solutions are produced by Sterilox's patented electrolytic generators, which offer a safe, single-use application for each patient as well as for each disinfecting cycle. They produce a powerful, application-specific disinfectant from water and common salt (sodium chloride), eliminating the concern about shelf stability of chemical storage. The Sterilox solutions have multiple use-specific clearances as a high-level disinfectant/sanitizer from the U.S. Food and Drug Administration (FDA) and the U.S. Environmental Protection Agency (EPA), as well as for disinfection and sterilization and as a wound irrigant in the United Kingdom and Europe. These clearances are supported by one of the largest libraries of disinfectant microbiology available in the world today.

Contact

Mark O'Connor (Press Contact)

KDS Marketing

610-594-9950

moconnor@kdsmarketing.com

Keith A. Goldan (Corporate Inquiries)

Chief Financial Officer

Sterilox Technologies, Inc.

610-341-1899

kgoldan@steriloxtechnologies.com

For more information, visit www.sterilox.com